Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.12
INVA's Cash-to-Debt is ranked lower than
93% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. INVA: 0.12 )
Ranked among companies with meaningful Cash-to-Debt only.
INVA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.12  Med: 1.3 Max: 321.73
Current: 0.12
0.12
321.73
Equity-to-Asset -0.77
INVA's Equity-to-Asset is ranked lower than
97% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. INVA: -0.77 )
Ranked among companies with meaningful Equity-to-Asset only.
INVA' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.04  Med: -0.31 Max: 0.67
Current: -0.77
-1.04
0.67
Debt-to-Equity -2.27
INVA's Debt-to-Equity is ranked lower than
99.99% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. INVA: -2.27 )
Ranked among companies with meaningful Debt-to-Equity only.
INVA' s Debt-to-Equity Range Over the Past 10 Years
Min: -7.71  Med: -1.2 Max: 28.14
Current: -2.27
-7.71
28.14
Debt-to-EBITDA 2.42
INVA's Debt-to-EBITDA is ranked lower than
67% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. INVA: 2.42 )
Ranked among companies with meaningful Debt-to-EBITDA only.
INVA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -29.66  Med: -2.23 Max: 15.61
Current: 2.42
-29.66
15.61
Interest Coverage 5.07
INVA's Interest Coverage is ranked lower than
92% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INVA: 5.07 )
Ranked among companies with meaningful Interest Coverage only.
INVA' s Interest Coverage Range Over the Past 10 Years
Min: 0.61  Med: 2.08 Max: 5.07
Current: 5.07
0.61
5.07
Piotroski F-Score: 8
Altman Z-Score: -2.06
Beneish M-Score: -1.95
WACC vs ROIC
10.44%
90.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 85.09
INVA's Operating Margin % is ranked higher than
99% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. INVA: 85.09 )
Ranked among companies with meaningful Operating Margin % only.
INVA' s Operating Margin % Range Over the Past 10 Years
Min: -635.37  Med: -354.6 Max: 85.09
Current: 85.09
-635.37
85.09
Net Margin % 64.11
INVA's Net Margin % is ranked higher than
97% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. INVA: 64.11 )
Ranked among companies with meaningful Net Margin % only.
INVA' s Net Margin % Range Over the Past 10 Years
Min: -3766.57  Med: -348.09 Max: 64.11
Current: 64.11
-3766.57
64.11
ROA % 40.82
INVA's ROA % is ranked higher than
98% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. INVA: 40.82 )
Ranked among companies with meaningful ROA % only.
INVA' s ROA % Range Over the Past 10 Years
Min: -47.04  Med: -30.27 Max: 40.82
Current: 40.82
-47.04
40.82
ROC (Joel Greenblatt) % 73205.19
INVA's ROC (Joel Greenblatt) % is ranked higher than
98% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. INVA: 73205.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
INVA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1062.05  Med: -368.28 Max: 73205.19
Current: 73205.19
-1062.05
73205.19
3-Year Revenue Growth Rate 189.10
INVA's 3-Year Revenue Growth Rate is ranked higher than
98% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. INVA: 189.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
INVA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 1.3 Max: 191
Current: 189.1
0
191
GuruFocus has detected 1 Warning Sign with Innoviva Inc INVA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INVA's 30-Y Financials

Financials (Next Earnings Date: 2018-07-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

INVA Guru Trades in Q2 2017

Michael Price 52,500 sh (New)
Joel Greenblatt 571,223 sh (+596.61%)
Steven Cohen 1,335,500 sh (+87.46%)
Jim Simons Sold Out
Seth Klarman Sold Out
First Eagle Investment 2,678,043 sh (-14.35%)
Paul Tudor Jones 37,369 sh (-57.42%)
» More
Q3 2017

INVA Guru Trades in Q3 2017

Chuck Royce 756 sh (New)
Jim Simons 1,060,380 sh (New)
Jeremy Grantham 14,600 sh (New)
Joel Greenblatt 589,067 sh (+3.12%)
Michael Price 52,500 sh (unchged)
Paul Tudor Jones Sold Out
First Eagle Investment 1,922,313 sh (-28.22%)
Steven Cohen 942,900 sh (-29.40%)
» More
Q4 2017

INVA Guru Trades in Q4 2017

Caxton Associates 18,037 sh (New)
Jim Simons 1,518,900 sh (+43.24%)
Steven Cohen 1,297,131 sh (+37.57%)
Chuck Royce 847 sh (+12.04%)
Michael Price 52,500 sh (unchged)
Jeremy Grantham 14,600 sh (unchged)
Joel Greenblatt 552,755 sh (-6.16%)
First Eagle Investment 1,288,150 sh (-32.99%)
» More
Q1 2018

INVA Guru Trades in Q1 2018

John Hussman 200,000 sh (New)
Paul Tudor Jones 99,099 sh (New)
Jim Simons 2,305,820 sh (+51.81%)
First Eagle Investment 1,364,550 sh (+5.93%)
Michael Price 52,500 sh (unchged)
Caxton Associates Sold Out
Jeremy Grantham Sold Out
Joel Greenblatt 544,869 sh (-1.43%)
Chuck Royce 673 sh (-20.54%)
Steven Cohen 433,869 sh (-66.55%)
» More
» Details

Insider Trades

Latest Guru Trades with INVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
First Eagle Investment 2018-03-31 Add 5.93%$13.8 - $16.99 $ 14.19-8%1,364,550
Joel Greenblatt 2018-03-31 Reduce -1.43%$13.8 - $16.99 $ 14.19-8%544,869
First Eagle Investment 2017-12-31 Reduce -32.99%0.02%$11.73 - $14.75 $ 14.196%1,288,150
Joel Greenblatt 2017-12-31 Reduce -6.16%0.01%$11.73 - $14.75 $ 14.196%552,755
First Eagle Investment 2017-09-30 Reduce -28.22%0.02%$12.06 - $14.11 $ 14.198%1,922,313
Joel Greenblatt 2017-09-30 Add 3.12%$12.06 - $14.11 $ 14.198%589,067
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:SZSE:002275, NAS:IMGN, NAS:SGMO, XSWX:SFZN, SZSE:000403, NAS:BOLD, NAS:XNCR, XPAR:DBV, OCSE:ALK B, SHSE:600645, NAS:EDIT, XTER:BIO3, TSE:4565, NAS:TBPH, NAS:WVE, NAS:GTHX, SZSE:300149, TSE:4592, OSTO:VITR, NAS:IOVA » details
Traded in other countries:HVE.Germany,
Headquarter Location:USA
Innoviva Inc is a biopharmaceutical company that is engaged in the discovery, development and commercialization of small molecule medicines. The firm collaborates with and receives funding from GlaxoSmithKline.

Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes RELVAR/BREO/ELLIPTA, ANORO, ELLIPTA, TRELEGY, ELLIPTA, and others. The firm collaborates with and receives funding from GlaxoSmithKline.

Ratios

vs
industry
vs
history
PE Ratio 11.08
INVA's PE Ratio is ranked higher than
78% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 29.83 vs. INVA: 11.08 )
Ranked among companies with meaningful PE Ratio only.
INVA' s PE Ratio Range Over the Past 10 Years
Min: 10.78  Med: 16.21 Max: 75.71
Current: 11.08
10.78
75.71
Forward PE Ratio 6.92
INVA's Forward PE Ratio is ranked higher than
96% of the 71 Companies
in the Global Biotechnology industry.

( Industry Median: 24.45 vs. INVA: 6.92 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 11.08
INVA's PE Ratio without NRI is ranked higher than
80% of the 255 Companies
in the Global Biotechnology industry.

( Industry Median: 30.45 vs. INVA: 11.08 )
Ranked among companies with meaningful PE Ratio without NRI only.
INVA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.78  Med: 16.21 Max: 75.71
Current: 11.08
10.78
75.71
Price-to-Owner-Earnings 11.88
INVA's Price-to-Owner-Earnings is ranked higher than
76% of the 148 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. INVA: 11.88 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
INVA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.56  Med: 20.66 Max: 321.75
Current: 11.88
11.56
321.75
PS Ratio 7.34
INVA's PS Ratio is ranked higher than
57% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INVA: 7.34 )
Ranked among companies with meaningful PS Ratio only.
INVA' s PS Ratio Range Over the Past 10 Years
Min: 7.12  Med: 31.4 Max: 1600
Current: 7.34
7.12
1600
Price-to-Free-Cash-Flow 10.21
INVA's Price-to-Free-Cash-Flow is ranked higher than
77% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 33.20 vs. INVA: 10.21 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
INVA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.91  Med: 20.59 Max: 139.55
Current: 10.21
9.91
139.55
Price-to-Operating-Cash-Flow 10.21
INVA's Price-to-Operating-Cash-Flow is ranked higher than
74% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 30.32 vs. INVA: 10.21 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
INVA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.91  Med: 20.59 Max: 139.55
Current: 10.21
9.91
139.55
EV-to-EBIT 10.03
INVA's EV-to-EBIT is ranked higher than
73% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. INVA: 10.03 )
Ranked among companies with meaningful EV-to-EBIT only.
INVA' s EV-to-EBIT Range Over the Past 10 Years
Min: -813.9  Med: -10 Max: 193.7
Current: 10.03
-813.9
193.7
EV-to-EBITDA 9.34
INVA's EV-to-EBITDA is ranked higher than
73% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. INVA: 9.34 )
Ranked among companies with meaningful EV-to-EBITDA only.
INVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -387.5  Med: -9.9 Max: 360.3
Current: 9.34
-387.5
360.3
EV-to-Revenue 8.16
INVA's EV-to-Revenue is ranked higher than
57% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. INVA: 8.16 )
Ranked among companies with meaningful EV-to-Revenue only.
INVA' s EV-to-Revenue Range Over the Past 10 Years
Min: 8.5  Med: 33.2 Max: 1849.5
Current: 8.16
8.5
1849.5
Current Ratio 27.85
INVA's Current Ratio is ranked higher than
62% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. INVA: 27.85 )
Ranked among companies with meaningful Current Ratio only.
INVA' s Current Ratio Range Over the Past 10 Years
Min: 2.41  Med: 6.62 Max: 27.85
Current: 27.85
2.41
27.85
Quick Ratio 27.85
INVA's Quick Ratio is ranked higher than
63% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. INVA: 27.85 )
Ranked among companies with meaningful Quick Ratio only.
INVA' s Quick Ratio Range Over the Past 10 Years
Min: 2.41  Med: 6.62 Max: 27.85
Current: 27.85
2.41
27.85

Buy Back

vs
industry
vs
history
3-Year Dividend Growth Rate -100.00
INVA's 3-Year Dividend Growth Rate is ranked lower than
86% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.00 vs. INVA: -100.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
INVA' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -100
Current: -100
3-Year Average Share Buyback Ratio 4.30
INVA's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. INVA: 4.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -140.4  Med: -10.2 Max: 4.3
Current: 4.3
-140.4
4.3

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.23
INVA's Price-to-Median-PS-Value is ranked higher than
92% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. INVA: 0.23 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
INVA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 1.58 Max: 49.63
Current: 0.23
0.23
49.63
Earnings Yield (Greenblatt) % 9.97
INVA's Earnings Yield (Greenblatt) % is ranked higher than
93% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. INVA: 9.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
INVA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -44.3  Med: -1.4 Max: 10.07
Current: 9.97
-44.3
10.07

More Statistics

Revenue (TTM) (Mil) $229.11
EPS (TTM) $ 1.28
Beta1.54
Volatility26.93%
52-Week Range $11.47 - 17.99
Shares Outstanding (Mil)101.47

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 284 312 317
EBIT (Mil $)
EBITDA (Mil $) 261 288 292
EPS ($) 1.73 1.90 1.94
EPS without NRI ($) 1.73 1.90 1.94
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 88
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}